Pradžia › Alfa-1 antitripsino trūkumas › Kalifornija
Alfa-1 antitripsino trūkumas klinikiniai tyrimai Kalifornija
4 tyrimai dėl Alfa-1 antitripsino trūkumas ieško dalyvių vietose Kalifornija.
Miestai Kalifornija
Oficialus tyrimo tekstas (anglų kalba)
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 100, Los Angelas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-08-11 · NCT07555483Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
- University of California San Diego, Altman Clinical and Translational Institute, La Jolla
- UCLA Pulmonary and Critical Care, Los Angeles
- Stanford University, Palo Alto
- ir dar 1
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-05-13 · NCT05677971Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
- University of California San Diego, La Jolla
- UCLA Pulmonary and Critical Care, Los Angeles
- University of California Benioff Children's Hospital, San Francisco
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-03-05 · NCT06165341PiMZ Longitudinal Cohort (PiMZ Logic)
- University of California- Los Angeles, Los Angeles
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-01-16 · NCT06505603Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.